Overview

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours

Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human study is to evaluate the safety and tolerability of escalating doses of ODM-203 in subjects with advanced solid tumours and to determine the maximum tolerated dose and dose limiting toxicities.
Phase:
Phase 1
Details
Lead Sponsor:
Orion Corporation, Orion Pharma